Marker Therapeutics, Inc.

Monthly Archives: December 2015

TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

…JACKSONVILLE, Florida, December 10, 2015

Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients
Provides catalyst to start Phase II studies
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today presented new data at the San Antonio Breast Cancer Symposium in the poster titled, “Robust generation of T-cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine.” The poster was co-authored by Dr.

Read More

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

…TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015 San Antonio Breast Cancer Symposium, which will be held in San Antonio, Texas on December 8 – 12, 2015.

Read More